{"id":1021806,"date":"2026-11-17T10:53:12","date_gmt":"2026-11-17T15:53:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/"},"modified":"2026-11-17T10:53:12","modified_gmt":"2026-11-17T15:53:12","slug":"annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/","title":{"rendered":"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MALVERN, Pa., Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company\u2019s pivotal Phase 3 trial in early AD, after the review of the study\u2019s safety data. This 12-month review follows the DSMB\u2019s positive 6-month feedback, which was <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ziBXmhP3KPrQfSlyAWQKWyxj2A5InZeo40QrbBfE61KDEN5_rdgv8gFvGqlJQ3RKIP2N8KpE-Pqu8ELYSo3PAFykkSJmNqFQTcMHfSD1omlHfEJWgtskpkRaUgx7xsVWEgH0PkaDi3jECr5ag0_MuA==\" rel=\"nofollow\" target=\"_blank\">announced in February 2026<\/a>.<\/p>\n<p>The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing. <\/p>\n<p>\u201cA second positive recommendation from the DSMB in such a large population further reinforces our confidence in buntanetap\u2019s safety profile,\u201d said Cheng Fang, Ph.D., Chief Scientific Officer at Annovis. \u201cThis milestone comes at an important time. As we approach the 6-month data readout and prepare for regulatory submission, a demonstrated safety at scale is essential. In March, we will report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results.\u201d<\/p>\n<p>DUET-AD (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3he7hHKBA_V4joZ1WblWk_LHuXMFkeIhKcnH1IygpZHm2yvydV1GFMGeEDz97Dhd9qAmiDYEeVkD8aJ0crlG-I8d84ZdkTSSqJaouoDe8oLvWRS-cmCPXJZNb4clok1y\" rel=\"nofollow\" target=\"_blank\">NCT06709014<\/a>) remains on track, with last patient, last visit for the 6-month treatment period expected on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027.<\/p>\n<p>\n        <strong>About Annovis<\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD). The Company&#8217;s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6wxSnko2PSesbt4kBSGvW9SdxGKeKZIN8aoX9UcXVbr_vCPztLWcGwEC7RMnn3EHKUIT2a5Yf9-3MkH0oZr4l8pN8l8p7izOXLl8jwM07anAKsDtUZYuvlKhDEW-vkBez86s5ZIUu0waqQnvFa2oojB3EtWQA1b1S3s2hme_47IorjugZrMPWsA_jCMprlrJSEd_SHlmBhU2S1o3eZpud-eiYW4h0Fau4u3NuSnAyHN1qoBYzoeaolYh5i_A7lAFm1ElvD8YeSVNLz9pc7ACbg==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pm4Mn8AD_m_zaY_p1sPfxaLo3fBMZGcwcyvh4t9sEoA5Ghtq3EWvVgaCY4k9Cs1yoIZyjexZCwcT7fhtLCclrK-aBSneLAE2MEpMCvDHB2vWdlrvQM1Bi7UDPmtwwX4SVL5SsCGcJ8Mc0yi5zyU7bOoER0rsjoV7c1j2LfJ_t51f_TcLDe8v94joUrZRPpsr7FaRL095qxNX4OcnetoPCvVoXlpWY_G1l7a43Q-qu-vlINoNLSKylI26IuhxZF65E-GvmysfaqKEEm2HNEkIi3xuE5DHDJjgjjQuzWXX7ZcsVfBHEaRIWhsjaGZZoeRQ\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RtEe6EyN7U1hLUNxM3_amAnAynEa7P9fMf6RfMI36XSm1fvQY0w116tGlTg32gMcdXc6joMOY8OB3u1YNjj0ZOCFvIQ2MLXoyjOtpjOa47eL01WDj1NTtxMGg2MLI51m56j7O4kcNiiH_65HgfqS8De25AN--ibzM-lFboPFXZsEzkyOgTl0mNkCm9LXEe1ct30ObCbausoTlPWDccH2WB402xN46LDS8RrT5l2KQ3nKdrywStKZbHw5U8cVy4Dc\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0m-CpCas1VtcE1pu6T-tWF-sU_CR9OL0jj4ObPHbPKJ8yhMGwHWX5AB3Gg8BB8oZlkp0UKGyet4fXgFKJ8zqawxJf_4lpwCGcOEmOCq2hNgWYz3xxMV4SLR0slMoixjL0eIc9lkMOVmNFASNB8BxEEZspt7R7is0oLNexSt96WlViXb7k2jDmP8qP0j_G9sGJ-NhUs0sKGwMk6KHXY0cAw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IsdhPkfltJGRDaVFeNaXC4weC5KctkyOFlIIhdhmkhSmBLVQKmBwu2m4Gzp6T0P6MRjgXIKr6QZAQSmP7FrqcuvO10IdEGq7qqVYQoQc2_rPsfZnkUTeKlD2Ea0vRdK_NIoOC1I0TUKbu3lCY5p543f9Ag1jDb8d0kNKxEcB8_BlnoeGLdzVHrTdFShsJNna0OQN6Nr90oWkel2PjAU_xz3zx9QjfE_g1Kqeuo2bOmVcQKbpCOKh1ZmqoGbrGkOEigrx4UZS-Qx6X_ThxMazHxLUhQzFxmgVTybi6CawTCTq_GMAvHFAw7HpIcHQyT6x70g06v0ROMOWgi31cPvbWdVyb6KPNNKbUlJl0RvJI9g=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6wxSnko2PSesbt4kBSGvW_U1paXT7QKtz-gC4FlchBI_uXhxxgE1OhG-spth9wM6lXyOlK0B-MzuKs-leil66hlrpP5taUFmG-ji7kjcJx0ZfESi6Qlf3BeiZE-q0_aDQIlrMvPyqE6dKSG120e8tX6Tku1oWHitc2_zWNz6BgoPQSWQVCEYnXpLUVfiUTOnKXExVN5RAr3hWazWKBzVPMOo9lRXPUrwMg0FBQhKw6XLnw1lxgEdCquqPhOUwshgaxLGyI7IUTBdDS4wVGSOsw==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ap40sYDGDRCgspb7LCxUM20ZcmZ8_G2Vnns5m3t4Z3qOkxEqvgnCZNr-RYn70ohDyMB_Z01awjoKcQcKqbAybUkO04s6LD7ioZx9m5NsGPI=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTA5N2QxNzgtZWY5ZC00MTFlLTk2N2MtMTlmMTg1YTZiNDc2LTEyMDY0MDMtMjAyNi0xMS0xNy1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company\u2019s pivotal Phase 3 trial in early AD, after the review of the study\u2019s safety data. This 12-month review follows the DSMB\u2019s positive 6-month feedback, which was announced in February 2026. The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing. \u201cA second positive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021806","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company\u2019s pivotal Phase 3 trial in early AD, after the review of the study\u2019s safety data. This 12-month review follows the DSMB\u2019s positive 6-month feedback, which was announced in February 2026. The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing. \u201cA second positive &hellip; Continue reading &quot;Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T15:53:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study\",\"datePublished\":\"2026-11-17T15:53:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/\"},\"wordCount\":455,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/\",\"name\":\"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=\",\"datePublished\":\"2026-11-17T15:53:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - Market Newsdesk","og_description":"MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company\u2019s pivotal Phase 3 trial in early AD, after the review of the study\u2019s safety data. This 12-month review follows the DSMB\u2019s positive 6-month feedback, which was announced in February 2026. The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing. \u201cA second positive &hellip; Continue reading \"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-17T15:53:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study","datePublished":"2026-11-17T15:53:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/"},"wordCount":455,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/","name":"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=","datePublished":"2026-11-17T15:53:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTExMSM3OTcwMDU4IzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021806"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021806\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}